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Abstract
Background Survival after pancreatic head adenocarci-
noma surgery is determined by tumor characteristics,
resection margins, and adjuvant chemotherapy. Few studies
have analyzed the long-term impact of postoperative
morbidity. The aim of the present study was to assess the
impact of postoperative complications on long-term sur-
vival after pancreaticoduodenectomy for cancer.
Methods Of 294 consecutive pancreatectomies performed
between January 2000 and July 2011, a total of 101 pan-
creatic head resections for pancreatic ductal adenocarci-
noma were retrospectively analyzed. Postoperative
complications were classified on a five-grade validated
scale and were correlated with long-term survival. Grade
IIIb to IVb complications were defined as severe.
Results Postoperative mortality and morbidity were 5 and
57 %, respectively. Severe postoperative complications
occurred in 16 patients (16 %). Median overall survival
was 1.4 years. Significant prognostic factors of survival
were the N-stage of the tumor (median survival 3.4 years
for N0 vs. 1.3 years for N1, p = 0.018) and R status of the
resection (median survival 1.6 years for R0 vs. 1.2 years
for R1, p = 0.038). Median survival after severe postop-
erative complications was decreased from 1.9 to 1.2 years
(p = 0.06). Median survival for N0 or N1 tumor or after
R0 resection was not influenced by the occurrence and
severity of complications, but patients with a R1 resection
and severe complications showed a worsened median sur-
vival of 0.6 vs. 2.0 years without severe complications
(p = 0.0005).
Conclusions Postoperative severe morbidity per se had
no impact on long-term survival except in patients with R1
tumor resection. These results suggest that severe compli-
cations after R1 resection predict poor outcome.
Introduction
Modern treatment of pancreatic cancer has become multi-
disciplinary, but surgery still plays a pivotal role. Its overall
impact on long-term survival remains important. The ulti-
mate goal of surgery has not changed, and radical local
resection must be attempted to achieve a high R0 resection
rate [1]. Until recently, a high postoperative morbidity rate
had been considered acceptable [2–4]. It must be taken into
account that operative indications have been expanded to
include, for example, routine portal vein resection. Also, an
increasing number of elderly patients with severe co-mor-
bidities are nowadays considered surgical candidates. To
offset these negative factors, advances in perioperative
medicine and centralization of pancreas surgery have had a
positive effect on mortality rates, which are currently\5 %
[5–7].
In the current literature, postoperative morbidity rates
range widely, from 20 % up to 70 % [2, 3, 7]. Notwith-
standing that postoperative complication rates are still
high, the large range indicates significant shortcomings in
regard to assessing and reporting complications. Indeed,
until recently, there were no standardized classifications of
pancreatic fistula, postoperative bleeding complications,
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and delayed gastric emptying after pancreas resection [8–
10]. The current widely accepted Dindo-Clavien compli-
cation classification now allows grading complications
according to their severity [11]. The clinical focus of
postoperative complications has been traditionally their
consequences on the short-term course. There is also good
evidence that increased morbidity negatively affects the
patient’s quality of life. Morbidity also has an impact on
health care resources (i.e., prolonged hospital stay, higher
costs) [12–15].
When assessing long-term outcome after pancreatic
cancer resection, technical aspects of surgery and tumor
characteristics have commonly been taken into account as
risk factors influencing survival. Favorable prognostic
factors are R0 resection, negative nodes, small tumor size,
and well-differentiated tumors without perineural or peri-
vascular invasion [16–18]. Moreover, postoperative adju-
vant chemotherapy has been shown to increase survival
[19, 20]. The role of postoperative complications on long-
term survival has been largely neglected until now. This is
especially true for pancreatic cancer surgery, with only a
few studies that have assessed this particular aspect.
Therefore, the aim of the current study was to assess the
impact of postoperative complications, stratified by their
severity, on long-term survival of patients after pancreatic
head resection for ductal adenocarcinoma.
Materials and Methods
Patients and Data Collection
A database including more than 150 items for each patient
who underwent pancreas resection at the Department of
Visceral Surgery, University Hospital of Lausanne
(CHUV) has been established. Patients who were operated
on from 2000 to 2008 were retrospectively entered, while
patients operated since 2009 were prospectively entered.
Only patients who underwent pancreatic head resection
for pancreatic ductal adenocarcinoma from January 2000 to
July 2011 were included. Among the 294 patients regis-
tered, 101 pancreaticoduodenectomies (PDs) for pancreatic
ductal adenocarcinomas were identified and selected for
further analysis. Not included were all cases of ampullary
adenocarcinoma, common bile duct adenocarcinoma,
duodenal cancer, and resections for benign disease. Also
excluded were patients who underwent total pancreatec-
tomy and pancreatic left resection. Patients who died dur-
ing hospitalization for PD were excluded because this
study focused solely on the outcome of patients surviving
the index operation.
Survival data were obtained by reviewing hospital
records and/or the local tumor registry or by direct
contacting the individual patient. Informed consent was
obtained from all patients. The local ethics committee
approved the study.
Assessment of Postoperative Morbidity and Mortality
Postoperative mortality was defined as patient death during
the first 30 days postoperatively or during hospitalization
following pancreatic head resection. Postoperative mor-
bidity was assessed with the focus on postoperative sur-
gery-related complications that were identified according
to most recent international definitions [8–10]. Postopera-
tive nonsurgical morbidity was also recorded taking into
account every event that deviated from the normal opera-
tive course. Postoperative complications were defined as all
medical and surgical complications that occurred during
the hospitalization for PD.
Specific definitions for surgical complications were
used: pancreatic fistula—any measurable volume of fluid
from a drain on or after postoperative day (POD) 3 with an
amylase level more than three times the serum amylase
activity [8]; delayed gastric emptying—inability to return
to a standard diet by the end of the first postoperative week
or prolonged (C4 days) nasogastric intubation [10]; hem-
orrhage—blood loss from a drain or nasogastric tube,
transfusion C3 units packed red blood cells, or the need for
invasive treatment [9]. Other postoperative complications
recorded were intraabdominal infection (fluid or abscess),
wound infection, bile leak, gastric leak, small bowel
obstruction, portal vein thrombosis, and cholangitis.
Complications were graded according to their severity
on a validated five-point scale (grades I, II, IIIa–b, IVa–b,
V) [11]. Complications requiring treatment under general
anesthesia or intensive care unit treatment—graded IIIb to
IVb—were defined as severe complications.
Pathologic staging was performed according to the
American Joint Committee on Cancer guidelines on TNM
staging (www.cancerstaging.org). Surgical margins were
assessed and considered R1 if microscopic tumor invasion
was present at the resection margin.
Definitions of Risk Factors
Alcohol intake was estimated and classified according to
national guidelines (www.sfa-ispa.ch, Swiss Federal
Commission for Alcohol Problems): Regular daily alcohol
consumption should be limited for men and women to
B25 g of pure alcohol. Smoking was defined as active
smoking at the time the pancreatic cancer was diagnosed or
a positive smoking history. Jaundice was defined as the
clinical signs of yellow colorization of the skin and eyes as
well as bilirubin levels [2 mg/l (34 lmol/L). Any
unwanted weight loss that occurred simultaneously or
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within 3 months prior to the diagnosis of pancreatic cancer
was assessed as a risk factor (‘‘weight loss’’).
Data Analysis
The impact of complications and their severity on long-
term outcome was assessed. If a patient had several com-
plications, the one with the highest grade was chosen for
further analysis. The patients were then stratified according
to resection margin status (R0 vs. R1/2). Student’s t test,
the v2 test, and Fisher’s exact test were used for the uni-
variate analysis to detect the patient’s operative or patho-
logic factors that could predict the occurrence of
postoperative complications.
The median survival and overall survival rates were
determined using Kaplan-Meier survival curves. Overall
survival was defined as the time span from the index
operation to the date of death for any reason. The log-rank
test was used for comparison of different variables. Sig-
nificant parameters on univariate analysis were taken into
account for subsequent multivariate analysis using Cox’s
proportional hazard regression. Differences were consid-
ered significant at p \ 0.05. The mean follow-up time was
1.7 ± 1.4 years.
Results
Complications
There were 101 PDs performed in 57 men and 44 women
with a mean age of 68 years (range 39–85 years) for
pancreatic ductal adenocarcinoma. The early mortality rate
related to the index operation (grade V complications, in-
hospital mortality) was 5 % (n = 5). These five patients
were excluded from further analysis of long-term outcome
(Table 1).
A total of 58 patients were found to have complications.
Hence the overall complication rate was 57 % (58/101
patients with complications grades I–IV). Among the 101
patients, 16 (16 %) developed severe postoperative com-
plications (grades IIIb, IVa, IVb). The distribution of the
grades and types of complications is shown in Table 1.
Length of Hospital Stay and Complication-Related
Delay of Adjuvant Treatment
Length of hospital stay (LOS) after the index operation was
strongly correlated with the occurrence and severity of
postoperative complications. The overall median LOS was
18 days (mean 22 ± 12 days, range 8–72 days), which
was similar to those without severe complications (median
17 days, mean 18 ± 8 days, range 8–45 days). In the case
of severe postoperative complications (grades III, IV), the
mean hospital stay was significantly prolonged, up to
39 ± 17 days (p \ 0.0001). The mean LOSs stratified by
the severity of complications were 18, 23, and 25 days for
complications of grades I, II, and IIIa, respectively, com-
pared to 38, 37, and 42 days for grades IIIb, Iva, and IVb.
These data clearly show increased LOS for patients with
severe postoperative complications.
Of the 96 patients who survived the index operation, 45
(47 %) benefited from postoperative adjuvant treatment.
The proportions of patients who did or did not receive
adjuvant treatment after encountering severe postoperative
complications was equal: In all, 8 (50 %) patients with
severe postoperative complications had adjuvant chemo-
therapy, as did 36 (45 %) patients without severe postop-
erative complications (p = 0.8). However, the patients
with severe complications experienced a significantly
prolonged interval between PD and the beginning of
adjuvant chemotherapy (mean 82 days, median 76 days)
compared to patients with no or minor complications
(mean 55 days, median 49 days) (p = 0.0051).
Risk Factors
As shown in Table 2, there were no specific preoperative or
intraoperative risk factors that were related with the pos-
sible occurrence of severe postoperative complications.
Patients with preoperative co-morbidities (smoking, alco-
hol abuse, cardiac or pulmonary disease, diabetes mellitus)
were not at increased risk for postoperative severe com-
plications. In addition, neither the type of reconstruction of
the pancreaticoenteric drainage nor the need of a vascular
resection was associated with an increased risk for severe
complications.
Analysis of Long-Term Survival
The median survival of the overall patient group was
1.4 years (range 0.3–8.9 years), and the 1-, 3-, and 5-year
survival rates were 66, 30, and 15%, respectively. Among
the various factors that have been analyzed, N status and R
status were statistically significant risk factors with a
negative impact on long-term survival. Long-term survival
of patients with severe complications was 1.2 years com-
pared to 1.9 years for patients without severe complica-
tions—of note, the difference was not statistically
significant (Table 3). A multivariate analysis showed that
only R0 resection was a significant predictor of survival
[hazard ratio (HR) 0.59; 95 % confidence interval (CI)
0.35–1.00; p = 0.05). In a subgroup analysis assessing
long-term survival of patients with R0 versus R1 resection
and the occurrence of severe complications, patients with
R1 resections and severe complications had significant
World J Surg (2013) 37:1901–1908 1903
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worse outcome (2.0 years vs. 0.6 years, p = 0.0005)
(Table 4; Fig. 1). Corresponding trends were identified for
N0 and N1 stages, although they did not reach statistical
significance.
Discussion
Successful treatment of pancreatic ductal adenocarcinoma
is nowadays not based solely on surgery but also on on-
cologic treatment using chemotherapy alone or combined
chemoradiation. Nevertheless, complete tumor resection
with attenuated morbidity must be attempted in all patients
with resectable disease. The current trial has been per-
formed to assess the impact of postoperative complications
stratified according to their severity on long-term survival
after pancreatic head resection for cancer. It demonstrated
that morbidity after PD is high (57 %), and that severe
postoperative complications (grade IIIb to IVb) occurred in
16 % of patients. Long-term survival was predominantly
Table 1 Morbidity after pancreaticoduodenectomy for ductal ade-
nocarcinoma (n = 101)
Morbidity No. %
Total no. 58 57.0
Complication grade
I 10 9.9
II 21 20.8
IIIa 11 10.9
IIIb 9 8.9
IVa 3 3.0
IVb 4 4.0
Severe complications (CIIIb)
No 80 79.0
Yes 16 16.0
Type of complication
Delayed gastric emptying 21 20.8
Wound infection 19 18.8
Extraabdominal infection 19 18.8
Pancreatic fistula 9 8.9
Hemorrhage 9 8.9
Intraabdominal infection 8 7.9
Portal vein thrombosis 3 3.0
Cholangitis 4 4.0
Respiratory failure 6 5.9
Small bowel obstruction 3 3.0
Cardiac 3 3.0
Pulmonary embolism 3 3.0
Gastric leak 2 2.0
Bile leak 2 2.0
Others 2 2.0
Table 2 Potential parameters influencing occurrence of severe
postoperative complications
Variable No severe
complications
(n = 80)
Severe
complications
(n = 16)
p
Age (years) 67 67 0.89
Age 1.0
[70 years 34 7
\70 years 46 9
Sex 0.78
Male 44 10
Female 36 6
Smoking 0.77
No 54 10
Yes 26 6
Alcohol abuse 0.24
No 70 12
Yes 10 4
Cardiac co-morbidity 0.51
No 61 14
Yes 19 2
Pulmonary co-morbidity 0.36
No 73 13
Yes 7 3
Diabetes mellitus 0.52
No 62 11
Yes 18 5
BMI (kg/m2) 25 25 0.74
Weight loss 0.42
No 46 7
Yes 34 9
Jaundice 0.76
No 21 5
Yes 59 11
Biliary stent 0.26
No 35 6
Yes 45 10
ASA 0.35
I 4 2
II 56 11
III 18 3
IV 1 0
Operating
time (min)
361 382 0.39
Vascular reconstruction 0.37
No 59 10
Yes 21 6
Pancreatic anastomosis 0.58
PJ 46 11
PG 33 5
T stage 0.36
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determined by tumor-related factors, such as N-stage and R
status. Postoperative complications per se had no impact on
survival, but they contributed to a worse prognosis when
they were in patients at risk for early tumor recurrence (i.e.,
in case of incomplete tumor resection, R1/2).
The traditional approach to looking at complications is
based on a short-term perspective and therefore is focused
on the hospital LOS, costs, and consumption of health care
resources [13–15]. Also, complications are often used as a
surrogate parameter to estimate the quality of surgery.
More recently, the long-term consequences of complica-
tions with their possible impact on quality of life, use of
adjuvant treatment, and most importantly survival time has
gained more attention as hitherto underestimated issues. In
most series, the impact of complications has been assessed
as an additional endpoint, among others, and some recently
published trials were focused on that particular aspect as
the primary point of interest [1, 6, 11, 21–26]. The results
have been somewhat controversial.
DeOliveira et al. validated the Dindo-Clavien classifi-
cation of complications in a large series of pancreatic
resections at Johns Hopkins Hospital. Despite the fact that
no statistically significant correlation between the type and
severity of complications with long-term survival could be
detected, patients with a grade IV pancreatic fistula had a
worse outcome than patients with grade II and III pancre-
atic fistulas [11]. Another randomized controlled trial from
the same institution evaluated the role of extended retro-
peritoneal lymphadenectomy for periampullary adenocar-
cinoma. It found that although increased morbidity was
observed in patients with an extended resection the long-
term survival remained unchanged [21]. It can be specu-
lated whether a possible oncologic benefit of a more radical
resection may be reversed by more complications. Patients
who were included in the ESPAC-1 trial were separately
Table 3 Potential parameters influencing long-term survival after
pancreaticoduodenectomy (n = 96)
Parameter Median survival (years) p
Sex 0.40
Male 1.8
Female 1.3
Age 0.29
\70 years 1.3
[70 years 1.8
Smoking 0.12
No 1.9
Yes 1.1
Alcohol abuse 0.90
No 1.3
Yes 2.0
ASA 0.52
I 3.0
II 1.7
III 1.1
IV –
T stage 0.076
T1 –
T2 1.8
T3 1.3
T4 0.9
N stage 0.018
N0 3.4
N1 1.3
Tumor differentiation 0.52
Well 2.5
Moderate 1.4
Poor 1.1
R status 0.0376
R0 1.6
R1 1.2
Tumor size (mm) 0.44
\30 1.8
C30 1.2
Adjuvant chemotherapy 0.82
No 1.6
Yes 1.4
Severe complications 0.06
No 1.9
Yes 1.2
ASA: American Society of Anesthesiologists
Table 2 continued
Variable No severe
complications
(n = 80)
Severe
complications
(n = 16)
p
T1 2 1
T2 15 1
T3 54 10
T4 7 3
N stage 0.45
N0 14 1
N1 66 15
R status 0.27
R0 52 8
R1 28 8
Tumor differentiation
Well 11 2
Moderate 46 8
Poor 17 4 0.90
BMI body mass index; PJ pancreaticojejunal; PG pancreatogastric
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assessed regarding whether the type of surgery and the
occurrence of complications had a negative impact on
survival and the beneficial effects of adjuvant radioche-
motherapy. However, no such negative impact could be
detected [22].
In contrast, at least six studies reported a worse survival
caused by the occurrence of postoperative complications,
even if definitions of the severity of complications in three
studies were lacking [1, 24, 25]. One recent study assessed
complications with the Dindo-Clavien classification and
found that severe postoperative complications (grades III
and IV) predicted worse long-term survival, whereas
overall postoperative complications had no significant
influence [23]. Two other studies did not evaluate the
impact of complications directly, but the absence of post-
operative bile leaks and low systemic inflammatory
response predicted a better outcome after resection of
pancreatic adenocarcinoma [6, 26].
Long-term survival after surgery for pancreatic ductal
adenocarcinoma is influenced by many factors. For
example, tumor-related aspects play a pivotal role (i.e.,
tumor size and invasion, lymph node affection, tumor
differentiation, perineural or vascular invasion, resection
margins) [16, 18, 20, 27]. Of note, the presence of tumor
cells within 1 mm of the resection margin is considered a
R1 resection [28, 29]. Adjuvant chemotherapy is nowadays
accepted as a valuable treatment option to prolong survival
(ESPAC, German multicenter study) [22, 30, 31]. In our
series, N-stage and R status were statistically significant
predictive factors that had a major impact on outcome,
whereas tumor differentiation, adjuvant chemotherapy and
severe complications did not change long-term survival in
the overall patient group. However, patients with incom-
plete tumor resection (R1 or R2) who are at increased risk
for early tumor recurrence had a shortened long-term sur-
vival if severe complications were piggybacked.
The question then arises: How can these clinical observa-
tions can be explained? First, severe complications delay the
Table 4 Effect of complications on significant parameter of survival
after pancreaticoduodenectomy
Parameter Median survival (years) p
No severe
complications
Severe
complications
R status
R0 1.4 1.7 0.98
R1 2.0 0.6 0.0005
N status
N0 6.9 1.2 0.33
N1 1.3 1.3 0.17
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timely beginning of adjuvant chemotherapy. In our series, a
median delay of 27 days was observed in patients with severe
complications: The median time to adjuvant chemotherapy
was 86 days with severe complications and 49 days without
severe complications. The time between surgery and the
beginning of adjuvant chemotherapy was only 46 days in the
ESPAC-1 trial, and chemotherapy was found to prolong sur-
vival [22]. Effective management of postoperative compli-
cations necessitates resources of experienced, high-volume
centers. Indeed, the effects of hospital and surgeon case vol-
umes on mortality after pancreatic resection is well docu-
mented [7, 32–35]. Second, mortality related to complications
can occur with a delay of several weeks. For example, major
visceral arterial bleeding caused by a ruptured pseudoaneu-
rysm has been described up to 30 weeks after the index
operation and hence represents a late sequela of pancreatic
fistula [36, 37]. Third, impaired caloric intake and maldiges-
tion due to exocrine pancreatic insufficiency may induce
significant malnutrition. Such patients remain particularly
susceptible to infections. Fourth, persisting postoperative
weakness impairs regularly ambulation, and patients remain
in bed even when they discharged home. Thrombosis for-
mation and an increased risk of pulmonary embolism are
important consequences. Fifth, a significant number of
patients are not able to stop smoking. Active smoking pro-
motes tumor recurrence and infectious complications [38]. All
these aforementioned risks may be responsible for general
immunosuppression, causing more infections and, even
worse, reducing tumor suppression capacity with earlier
tumor recurrence or metastasis formation.
Underestimated features are the pathophysiologic
effects of postoperative complications. Postoperative sys-
temic inflammatory response syndrome (SIRS) depends on
the duration and magnitude of surgical interventions [39].
Severe postoperative complications can set off a SIRS with
high levels of markers of inflammation or infection, such as
C-reactive protein (CRP), procalcitonin, and interleukins.
Jamieson et al. demonstrated that systemic inflammatory
responses with increased CRP levels predicted the outcome
after pancreas head resection for ductal adenocarcinoma
[26]. Postoperative inflammatory response certainly affects
the host-versus-tumor response and possibly tumor biol-
ogy, which could be deleterious particularly after incom-
plete resection [40].
Conclusions
Postoperative morbidity, in particular severe complica-
tions, has a deleterious effect on long-term survival after
pancreatic head resection for cancer. Its role may have
been underestimated so far, and more attention must be
given to its prevention and effective treatment.
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